Document ID: chunk:federal_register_of_legislation:F2025C00158:clause:4_1:p20
Version: federal_register_of_legislation:F2025C00158
Segment Type: clause
Provision Reference: sch 4 cl 1 (pt 20/381)
Character Range: 11586229–11599692

or recommencement of treatment after a break in biological medicine of less than 5 years) restriction to complete 18 to 20 weeks treatment; or
                                                                                                                                                                    Patient must have received insufficient therapy with this drug for this condition under the Initial 3 (recommencement of treatment after a break in biological medicine of more than 5 years) restriction to complete 18 to 20 weeks treatment; AND
                                                                                                                                                                    The treatment must provide no more than the balance of up to 20 weeks treatment; AND
                                                                                                                                                                    Must be treated by a rheumatologist.  or
                                                                                                                                                                    Must be treated by a clinical immunologist with expertise in the management of non-radiographic axial spondyloarthritis.
C10464              P10464         CN10464          Budesonide with formoterol                                                                                      Mild asthma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 10464
                                                                                                                                                                    Patient must have asthma and require an anti-inflammatory reliever therapy; AND
                                                                                                                                                                    Patient must not be on a concomitant single agent long-acting-beta-2-agonist (LABA).
                                                                                                                                                                    Device (inhaler) technique should be reviewed at each clinical visit and before initiating treatment with this medicine.
C10482              P10482         CN10482          Budesonide with formoterol                                                                                      Mild asthma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Compliance with Authority Required procedures - Streamlined Authority Code 10482
                                                                                                                                                                    Patient must have asthma and require an anti-inflammatory reliever therapy; AND
                                                                                                                                                                    Patient must not be on a concomitant single agent long-acting-beta-2-agonist (LABA);
                                                                                                                                                                    Patient must be aged 12 years or over.
                                                                                                                                                                    Device (inhaler) technique should be reviewed at each clinical visit and before initiating treatment with this medicine.
C10498              P10498         CN10498          Granisetron                                                                                                     Nausea and vomiting                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Compliance with Authority Required procedures - Streamlined Authority Code 10498
                                                                                                                                                                    The condition must be associated with radiotherapy being used to treat malignancy.  or
                                                                                                                                                                    The condition must be associated with oral chemotherapy being used to treat malignancy.
C10509              P10509         CN10509          Atezolizumab                                                                                                    Extensive-stage small cell lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 10509
                                                                                                                                                                    Continuing treatment - 4 weekly treatment regimen
                                                    Durvalumab                                                                                                      The treatment must be as monotherapy; AND
                                                                                                                                                                    Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
                                                                                                                                                                    Patient must not have developed disease progression while being treated with this drug for this condition.
C10521              P10521         CN10521          Atezolizumab                                                                                                    Extensive-stage small cell lung cancer                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 10521
                                                                                                                                                                    Continuing treatment - 3 weekly treatment regimen
                                                                                                                                                                    The treatment must be as monotherapy; AND
                                                                                                                                                                    Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND
                                                                                                                                                                    Patient must not have developed disease progression while being treated with this drug for this condition.
C10538              P10538         CN10538          Budesonide with formoterol                                                                                      Asthma                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    Compliance with Authority Required procedures - Streamlined Authority Code 10538
                                                                                                                                                                    Patient must have failed PBS-subsidised fluticasone proprionate and salmeterol as a fixed dose combination for this condition; AND
                                                                                                                                                                    Must be treated by a respiratory physician.  or
                                                                                                                                                                    Must be treated by a paediatrician.
C10560              P10560         CN10560          Tocilizumab                                                                                                     Systemic juvenile idiopathic